The European Alliance for Responsible R&D and Affordable medicines organised in cooperation with Wemos, SOMO, Salud por Derecho, StopAids and Global Justice Now a webinar on public investments in biomedical research and development (R&D).
The current biomedical R&D system is characterised by the lack of transparency over the amounts and sources of investment, including the contribution from the public. Organisations in the Netherlands, Spain and the UK have looked at various public funding streams that contributed to the development of new health products and proposed recommendations to ensure that the public investment results in medicines which are accessible, available and affordable.
The objective of the webinar was to identify commonalities in the situations in different European countries and to exchange of know-how on conducting similar reports.
Missed the webinar? Watch it back.
Or read the different reports:
- Netherlands – Wemos/SOMO – Overpriced – Drugs developed with Dutch public funding
- Spain – Salud por Derecho – The Public interest in Biomedical innovation
- UK – STOPAIDS/Global Justice Now – Pills and Profits: How drug companies make a killing out of public research
Share this